

This is a pre print version of the following article:


Phenotypic spectrum of NRXN1 mono- and bi-allelic deficiency: A systematic review / Castronovo, P.; Baccarin, M.; Ricciardello, A.; Picinelli, C.; Tomaiuolo, P.; Cucinotta, F.; Frittoli, M.; Lintas, C.; Sacco, R.; Persico, A. M.. - In: CLINICAL GENETICS. - ISSN 0009-9163. - 97:1(2020), pp. 125-137. [10.1111/cge.13537]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

20/04/2024 09:09

(Article begins on next page)



Phenotypic spectrum of NRXN1 mono- and bi-allelic deficiency: a systematic review

Journal:	<i>Clinical Genetics</i>
Manuscript ID	Draft
Manuscript Type:	Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Castronovo, Paola; Mafalda Luce Center for Pervasive Developmental Disorders, Child Neuropsychiatry Baccarin, Marco; Mafalda Luce Center for Pervasive Developmental Disorders, Child Neuropsychiatry Ricciardello, Arianna; Universita degli Studi di Messina, Interdepartmental Program "Autism 0-90" Picinelli, Chiara; Mafalda Luce Center for Pervasive Developmental Disorders, Child Neuropsychiatry Tomaiuolo, Pasquale; Mafalda Luce Center for Pervasive Developmental Disorders, Child Neuropsychiatry Cucinotta, Francesca; Universita degli Studi di Messina, Interdepartmental Program "Autism 0-90" Frittoli, Myriam; Mafalda Luce Center for Pervasive Developmental Disorders, Child Neuropsychiatry Lintas, Carla; Universita Campus Bio-Medico di Roma, Child and Adolescent Neuropsychiatry Sacco, Roberto; Universita Campus Bio-Medico di Roma, Child and Adolescent Neuropsychiatry Persico, Antonio; Universita degli Studi di Messina, Interdepartmental Program "Autism 0-90"
Key Words:	Autism Spectrum Disorder, Compound heterozygosity, Developmental delay, Neurexin1, Pitt-Hopkins-like syndrome 2, Schizophrenia

1
2
3
4 **Phenotypic spectrum of *NRXNI* mono- and bi-allelic deficiency:**
5
6
7 **a systematic review**
8
9

10
11
12 **P. Castronovo¹, M. Baccarin¹, A. Ricciardello², C. Picinelli¹, P. Tomaiuolo¹,**
13
14 **F. Cucinotta², M. Frittoli¹, C. Lintas³, R. Sacco³, A.M. Persico^{*2}**
15
16

17
18
19 ¹Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy

20
21 ²Interdepartmental Program “Autism 0-90”, “Gaetano Martino” University Hospital,
22
23 University of Messina, Messina, Italy

24
25 ³Service for Neurodevelopmental Disorders & Laboratory of Molecular Psychiatry and
26
27 Neurogenetics, University “Campus Bio-Medico”, Rome, Italy
28
29

30
31 **Running title:** *NRXNI* deficiency: a systematic review
32
33

34
35
36 **Conflict of Interest:** The authors declare no conflict of interest.
37
38

39
40 ***Correspondence:** Antonio M. Persico, Interdepartmental Program “Autism 0-90”, “G.
41
42 Martino” University Hospital, Via Consolare Valeria 1, I-98125 Messina, Italy.
43
44

45 Email: apersico@unime.it
46
47

48
49
50 **Funding information:** Italian Ministry of Health (Grant n. NET-2013-02355263) and
51
52 the EU Innovative Medicines Initiative Joint Undertaking, EU-AIMS (Grant n. 115300).
53
54
55
56
57
58
59
60

ABSTRACT

Neurexins are presynaptic cell adhesion molecules critically involved in synaptogenesis and vesicular neurotransmitter release. They are encoded by three genes (*NRXN1-3*), each yielding a longer alpha (α) and a shorter beta (β) transcript. Deletions spanning the promoter and the initial exons of the *NRXN1* gene, located in chromosome 2p16.3, are associated with a variety of neurodevelopmental, psychiatric, neurological and neuropsychological phenotypes. We have performed a systematic review to define (a) the clinical phenotypes most associated with mono-allelic exonic *NRXN1* deletions, and (b) the phenotypic features of *NRXN1* nullisomy due to compound heterozygous deletions/mutations. Clinically, three major conclusions can be drawn: (a) incomplete penetrance and pleiotropy do not allow reliable predictions of clinical outcome following prenatal detection of mono-allelic exonic *NRXN1* deletions. Newborn carriers should undergo periodic neuro-behavioral observations for the timely detection of warning signs and the prescription of early intervention; (b) the presence of additional independent genetic risk factors should always be sought, as they may influence prognosis; (c) children with exonic *NRXN1* deletions displaying early-onset, severe psychomotor delay in the context of a Pitt-Hopkins-like syndrome 2 phenotype, should undergo DNA sequencing of the spared *NRXN1* allele in search for mutations or very small insertions/deletions.

KEYWORDS

Autism Spectrum Disorder, compound heterozygosity, developmental delay, neurexin 1, Pitt-Hopkins-like syndrome 2, schizophrenia.

1. INTRODUCTION

1.1 Neurexin family proteins

Neurexins are presynaptic cell adhesion molecules critically involved in (a) synapse formation and maintenance, by establishing trans-synaptic complexes with postsynaptic ligands including neuroligins, neurexophilin, dystroglycan, LRRTM and cerebellin, among others; and in (b) vesicular neurotransmitter release, by coupling N- and P/Q-type calcium channels with the exocytotic machinery.¹ Three genes (*NRXN1-3*) are transcribed in neurons from two independent promoters, each yielding a longer alpha (α) and a shorter beta (β) isoform, composed of distinct extracellular domains linked to an identical intracellular sequence. Importantly, α -neurexins show a high degree of evolutionary conservation throughout vertebrates,^{2,3} while β -neurexins are not conserved.² In line with the evolutionary conservation of α -neurexins, triple knock-out mice lacking neurexin 1 α , 2 α and 3 α , but not β -neurexins, die on the first day of postnatal life, indicating that α -, and not β -neurexins, are essential for postnatal survival.⁴

The extracellular portion of α -neurexins encompasses six LNS (laminin/neurexin/sex hormone binding globulin) domains with three intercalated epidermal growth factor (EGF)-like domains, whereas the shorter β -neurexins have a single LNS domain. Neuroligins bind to the LNS domains of either α - or β -neurexins.⁵ Differential roles in synaptic transmission have been attributed to α - and β -neurexins, due to isoform-specific patterns of ligand interactions.⁶ The extraordinary degree of variation produced through alternative splicing both in neurexins and in neuroligins, profoundly influences intermolecular pairing affinities.⁵ All three neurexin genes contain five alternative splice sites (ss1–ss5), yielding nearly 4000 neurexin protein

1
2
3
4 isoforms.² One additional alternative splice site, later described only in the *NRXN1* and
5
6
7 *NRXN2* genes, is referred to as ss6 despite residing in the coding region of the fourth
8
9 LNS domain, between ss2 and ss3.⁷

13 **1.2 Neurexin 1 Copy Number Variation**

16 *NRXN1*, located on chromosome 2p16.3, is one of the largest known human genes, with
17
18 24 exons spanning 1.1 Mb. The promoter for neurexin-1 α transcripts lies upstream of
19
20 exon 1, while the promoter for neurexin-1 β is located in intron 17.⁸ The *NRXN1* locus is
21
22 particularly susceptible to non-recurrent deletions, resulting from chromosomal
23
24 rearrangements due to genomic instability.⁹ The molecular mechanisms giving rise to
25
26 these non-recurrent CNVs are very complex and still under investigation. Indeed
27
28 *NRXN1* deletions often occur in the vicinity of minus self-chains, a novel group of
29
30 LCRs consisting of short repeats (300-1000 bp) separated by several hundreds to a few
31
32 thousand nucleotides.¹⁰ These have been shown to cause genomic instability by
33
34 mediating secondary DNA structures potentially able to stall the replication fork and
35
36 cause template switching or to act as substrate for non-allelic homologous
37
38 recombination.¹¹ However, analyzing the local sequences surrounding the breakpoints
39
40 of 17 non-recurrent *NRXN1* deletions, Enggaard Hoeffding et al⁹ discovered two novel
41
42 sequence motifs and significantly higher AT nucleotide content at the breakpoints of all
43
44 17 deletions, compared to the overall nucleotide content on chromosome 2. Small
45
46 insertions and duplications giving rise to short microhomologous sequences were also
47
48 detected at the breakpoints. Hence, the two novel sequence motifs, together with a high
49
50 AT content, may increase genomic instability and enhance susceptibility to the
51
52
53
54
55
56
57
58
59
60

1
2
3
4 formation of single strand structures, potentially fostering repair of double strand breaks
5
6 by non-homologous end joining or leading to replication errors.⁹
7
8

9 Unlike recurrent deletions mediated by flanking terminal repeats, *NRXNI*
10 deletions vary in size and breakpoint location. Exonic *NRXNI* deletions are significantly
11 associated with neurodevelopmental and neuropsychiatric disorders, displaying an 8-
12 fold increase in prevalence among 19263 cases compared to 15624 controls (0.213% vs
13 0.026%, O.R. = 8.14).¹² Furthermore, 34% of these deletions were *de novo*,¹² supporting
14 relatively high, albeit not full penetrance, due to controls, parents and unaffected
15 siblings occasionally carrying the same CNV as the affected proband. Clinically
16 disruptive exonic *NRXNI* deletions usually span the promoter region and the first few
17 exons encoding the *NRXNI-α* transcript, which indeed represent the most critical
18 portion of the *NRXNI* gene.¹² In fact, in these individuals the *NRXNI-β* transcript is
19 often spared and individuals with deletions limited to the 3' end of the gene display a 7-
20 fold increased likelihood of carrying a second clinically relevant CNV, compared to
21 subjects with a *NRXNI* deletion affecting the 5' end.¹² Also genomic instability or
22 increased recombination rates could affect more frequently the 5' end of the gene,
23 enhancing the probability of deletions in the promoter region.¹³ Interestingly, these 5'
24 deletions encompass or indirectly influence the long noncoding RNA *AK127244*
25 adjacent to the promoter of *NRXNI-α*, increasingly involved in the etiology of several
26 neuropsychiatric disorders.¹⁴⁻¹⁷
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Contrary to exonic *NRXNI* deletions, cases and population-based controls do not
51 differ in prevalence of intronic *NRXNI* deletions.^{12,18,19} Furthermore, intronic *NRXNI*
52 deletion carriers are two-fold more likely to harbor a second clinically relevant CNV
53 compared to exonic *NRXNI* deletion cases.¹² Therefore, *NRXNI* intronic deletions do
54
55
56
57
58
59
60

1
2
3
4 not appear to substantially increase the risk for neurodevelopmental or neuropsychiatric
5 disorders. Also the effects of duplications and point mutations can greatly vary and
6
7 cannot be reliably predicted without specific functional studies.
8
9

10
11 Based on the evidence summarized above, this systematic review is focused on
12 mono- and bi-allelic exonic *NRXN1* deletions and their relationship with
13 neurodevelopmental/neuropsychiatric disorders or transdiagnostic neuropsychological
14 phenotypes.
15
16
17
18
19

20 21 22 **2. METHODS**

23 **2.1 Research strategy**

24
25 This systematic review has been conducted according to the Preferred Reporting Items
26 for Systematic reviews and Meta-Analysis (PRISMA) guidelines employing the
27 PubMed and Scopus databases (last update: November 30, 2018).²⁰ Both were searched
28 for full-length articles that discussed CNVs and *NRXN1* using the following search
29 terms:
30
31
32
33
34
35
36
37

38
39 $(NRXN1 \text{ OR Neurexin1}) \text{ AND Deletion.}$
40
41
42

43 **2.2 Study selection**

44
45 Articles were included in our review according to the following criteria: (a) English,
46 French, Italian, Spanish or German languages, (b) publication in peer reviewed journals,
47
48 (c) case-control studies or screenings for *NRXN1* exonic deletions in large clinically-
49 referred cohorts, and (d) case reports about *NRXN1* nullisomy. Articles were excluded
50 by title, abstract, or full text for irrelevance to the investigated issue. Finally, in order to
51 identify additional studies that could fulfill inclusion criteria, we also reviewed the
52
53
54
55
56
57
58
59
60

1
2
3
4 references listed in Béna et al²¹ and Dabell et al,¹³ the two major reviews published to
5
6 date on the clinical phenotypes associated with exonic *NRXN1* deletions.
7
8
9

10 11 **2.3 Data extraction and quality assessment**

12
13 Data were independently extracted by 2 reviewers (P.C., M.B.) according to the
14
15 Cochrane guidelines. A third reviewer (A.R.) then performed quality control on all data
16
17 extracted from each article, including: (a) total number and localization of mono-allelic
18
19 exonic *NRXN1* deletions; (b) total number of cases and controls analyzed; (c) type,
20
21 genomic coordinates and familial transmission of compound heterozygous *NRXN1*
22
23 deletions/mutations present in nullisomic patients, as well as (d) other molecular
24
25 findings, (e) family history and (f) clinical phenotype.
26
27
28
29
30
31

32 33 **2.4 Recruitment of a new case with *NRXN-1* nullisomy**

34
35 The new case of *NRXN-1* nullisomy hereby reported was recruited and clinically
36
37 characterized within the framework of an ongoing study on the genetics of Autism
38
39 Spectrum Disorder and neurodevelopmental delay, as previously described.²² This study
40
41 was approved by the Institutional Review Boards of University of Messina (Messina,
42
43 Italy) and University “Campus Bio-Medico” (Rome, Italy). Written informed consent
44
45 was provided by parents for themselves and for their children. A separate written
46
47 consent was provided for the publication of the clinical summary presented below and
48
49 of this patient’s photographs.
50
51
52
53
54

55 56 **3. RESULTS AND DISCUSSION**

57
58
59
60

1
2
3
4 The multi-step process and the number of articles retrieved at each step for this
5 systematic review is depicted in Figure 1. A total of 57 published studies was included
6
7 in this review. All 51 studies evaluating the frequency of monoallelic *NRXNI* exonic
8
9 deletions in clinically referred patient/control cohorts are listed in Table 1. Two of these
10
11 same studies, as well as 6 additional case reports describing *NRXNI* nullisomic patients
12
13 are listed in Table 2.
14
15
16
17
18
19

20 21 **3.1 Phenotypic spectrum of heterozygous *NRXNI* exonic deletions**

22 Heterozygous exonic microdeletions in *NRXNI* have been reported in association with
23
24 susceptibility to neurodevelopmental and neurocognitive disabilities, including
25
26 developmental delay (DD) and/or intellectual disability (ID), autism spectrum disorder
27
28 (ASD), schizophrenia and others (epilepsy, ADHD, Tourette syndrome, obsessive-
29
30 compulsive disorder, etc) (Table 1). Heterozygous deletions have also been found in
31
32 normal parents, siblings and healthy controls (Table 1), suggesting reduced penetrance
33
34 with gene-gene and gene-environment interactions influencing clinical features and
35
36 severity.
37
38
39

40
41 Several case-control studies have been published and thirty of them provide
42
43 control data for *NRXNI* (Table 1). Studies describing large numbers of cases and
44
45 controls have found statistically significant enrichment of exonic *NRXNI* deletions in
46
47 cases vs controls [0.18% vs 0.02%, respectively, $P < 0.0001$; OR=10.3 (7.03-15.06, 95%
48
49 confidence interval)], supporting a role for these deletions in the development of
50
51 abnormal phenotypes (Table 1). However, the possibility to reliably meta-analyze these
52
53 case-controls studies is undermined by the same control samples and data sets being
54
55 shared across more than one study.
56
57
58
59
60

1
2
3
4 In clinically ascertained populations, moderate-to-severe ID represents the
5 clinical phenotype most frequently associated with *NRXNI* exonic deletions (77–
6 92%).^{13,21,28} Other commonly co-occurring behavioral conditions include ASD (43–
7 70%),^{13,21,28,69,70} ADHD (9–41%),^{12,28} anxiety (6–7%)^{12,13} and schizophrenia (5%).¹²
8
9 Among neurological phenotypes, epilepsy has been reported in 14–53% of *NRXNI*
10 deletion carriers^{13,21,28,69} and muscle hypotonia in 38–47%.^{21,28} As expected for many of
11 the above-mentioned neurodevelopmental phenotypes, delays in receptive and/or
12 expressive language development have been consistently reported in children with
13 *NRXNI* deletions.^{13,21,25,27,60} Brignell et al⁷¹ made a comprehensive evaluation of speech
14 and language phenotypes, reporting speech difficulties in 69% of the patients with
15 *NRXNI* deletions.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Despite *NRXNI*'s widespread systemic expression and possible roles outside of
the nervous system,⁷² congenital anomalies are relatively rare, with the most prevalent
affecting skeletal muscle and heart.^{13,25,28,73} Mild dysmorphic features have been
described in 45–71% of the patients.^{13,21}

As discussed above, the majority of exonic *NRXNI* deletions identified in
clinical cases involves the promoter and the first few exons of the *NRXNI-α* transcript.
However, one published report supports an association between *NRXNI-β* deletions and
more severe phenotypes, possibly including enhanced prenatal lethality.⁷⁴ In particular,
a deletion of *NRXNI-β* exons 2-4, corresponding to *NRXNI-α* exons 19-22, carried by a
woman with a history of five first-trimester spontaneous abortions and diagnosed with
high-functioning autism, anxiety and depression, was transmitted to all four of her
children affected with autism, anxiety, developmental and speech delay, but not to an
unaffected child.⁷⁴ Deletions involving also *NRXNI-β* exons or *NRXNI-α* exons 6-17

1
2
3
4 may be associated with macrocephaly and seizures, according to some,^{13,28} though not
5
6 all studies.²¹ Apart from the involvement of *NRXNI-β*, increased phenotypic severity
7
8 may be due to *NRXNI-α* exon 6-17 deletions being in-frame and possibly yielding an
9
10 abnormal *NRXNI-α* protein, devoid of one or several of its extracellular domains,
11
12 responsible for a peculiar dominant negative effect.
13
14

15
16 The availability of knock-out mice carrying deletions of the promoter and first
17
18 exon of the *NRXNI-α* gene provides direct access to the biological effects of neurexin-
19
20 1α disruption on neurodevelopmental phenotypes. These rodent models recapitulate
21
22 some of the behavioral deficits observed in schizophrenia and ASD: mice lacking
23
24 *NRXNI-α* show impaired sensorimotor gating, increased grooming behavior, impaired
25
26 nest building and parenting abilities.⁷⁵ Parallel electrophysiological studies performed in
27
28 these same animals show weaker spontaneous and evoked excitatory synaptic
29
30 transmission, due to presynaptic glutamatergic deficits.⁷⁵ Neurexins' role in synapse
31
32 formation, functioning and alignment may thus well explain the reduced connectivity
33
34 between distant brain regions believed to underlie social cognition deficits
35
36 pathognomonic of ASD and the disorganization of thought processes typical of
37
38 schizophrenia. This conclusion is further reinforced by behavioral deficits, especially in
39
40 social memory, recorded even in heterozygous mice,⁷⁶ which usually do not display
41
42 behavioral phenotypes in rodent models of human neurodevelopmental disorders.
43
44
45
46
47

48 The putative effects of dysfunctional synaptic adhesion molecules, such as
49
50 *NRXNI*, on neural circuitry support pathophysiological theories postulating “two hit”
51
52 events as pivotal to neurodevelopmental disorders. In particular, the highly variable
53
54 clinical outcome associated with *NRXNI* deletions, ranging from unaffected carrier
55
56 status to severe neurodevelopmental phenotypes, suggests they may confer disease risk
57
58
59
60

1
2
3
4 rather than play a causal role *per se*. Incomplete penetrance may be explained by: (a)
5
6 secondary and independently segregating genetic risk factors, as supported by enhanced
7
8 frequencies of additional pathogenic CNVs in cohorts of patients carrying *NRXNI*
9
10 deletions;^{21,40} (b) exposure to environmental factors, especially active prenatally;^{77,78}
11
12 and/or (c) unfavorable stochastic events, able to synergistically foster the development
13
14 of clinical signs and of full-blown psychiatric disorders.²⁷ However, *NRXNI* deletion
15
16 carriers, even when apparently unaffected, seemingly share a common phenotype
17
18 characterized by high levels of anxiety, a dysexecutive syndrome with prominent
19
20 impulsivity, and borderline intelligence in the absence of aphasia, amnesia, agnosia,
21
22 and apraxia.^{79,80} These clinical features do not immediately fit into any single
23
24 nosological entity, but rather predispose to a variety of behavioral disorders. Additional
25
26 evidence comes from anedotal studies describing two mothers with a *NRXNI* deletion
27
28 apparently devoid of psychiatric disorder requiring treatment, but showing subclinical
29
30 depressive and anxiety symptoms as well as a dependent personality disorder.^{42,53}
31
32 Interestingly, high levels of anxiety are also characteristic of *NRXNI* knock-out mice,⁸¹
33
34 although they are not recorded in hz mice.⁷⁶ Collectively, these data highlight the need
35
36 for a thorough neuropsychological and psychiatric evaluation of apparently unaffected
37
38 *NRXNI* deletion carriers before providing clinical advice and genetic counseling (see
39
40 below).
41
42
43
44
45
46
47

48 Most studies performed to date present several limitations: (a) phenotypic
49
50 information on deletion-transmitting parents and on deletion-carrying siblings is
51
52 frequently lacking. This seriously limits the reliability of penetrance estimations,
53
54 currently ranging between 46% and 78%;^{25,27,61,70} (b) the majority of index cases are
55
56 children, not allowing accurate prevalence or penetrance estimations for adult-onset
57
58
59
60

1
2
3
4 neuropsychiatric conditions, e.g psychotic or mood disorders; (c) sample sizes are
5 usually small. These methodological limitations, paired with our insufficient
6 understanding of factors and processes influencing the clinical trajectory of *NRXNI*
7 deletions, pose a major challenge to genetic counseling over both prognosis and
8 recurrence risk.
9
10
11
12
13
14
15
16
17

18 **3.2 Phenotypic spectrum of *NRXNI* nullisomy**

19
20 *NRXNI* nullisomy, also referred to as Pitt-Hopkins-like syndrome 2 (OMIM n. 614325),
21 represents the “extreme” phenotype associated with *NRXNI* defects. In this condition,
22 compound heterozygous inherited *NRXNI* deletions/mutations produce a recessive and
23 extremely severe phenotype, including moderate to severe DD/ID, absence of
24 expressive language, muscle hypotonia, motor stereotypes, chronic constipation and
25 abnormal sleep/wake cycle. Only ten patients with *NRXNI* biallelic loss have been
26 reported to date (Figure 2).^{21,29,57,82-86} We shall now describe the clinical presentation of
27 a new case carrying compound heterozygous *NRXNI* deletions. The clinical phenotype
28 associated with biallelic *NRXNI* loss-of-function will be then reviewed, highlighting the
29 clinical features most consistently shared by the overall set of 11 known *NRXNI*-null
30 patients (Table 2).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **3.2.1 Clinical description of a new case of Pitt-Hopkins-like syndrome 2 with** 49 **compound heterozygous *NRXNI* deletion**

50
51 The proband is a 6 y.o. girl, second child of non-consanguineous parents with two other
52 children, a 9 y.o. girl with congenital deafness due to a connexin 26 mutation, and a 2½
53 y.o. girl in good health. Minor bleeding during the I trimester and diminished fetal
54
55
56
57
58
59
60

1
2
3
4 movements were reported. Born at full term, her birth weight was 2950 g, length 49 cm,
5
6 and Apgar score 9 at 1'. Parents observed greyish complexion, weak crying and arm
7
8 extraflexion during the first 12 hours of postnatal life. Remarkable muscle weakness,
9
10 hypotonia, reduced spontaneous activity and fatigability were present since birth.
11
12 Psychomotor development was profoundly delayed: postural control of head and trunk
13
14 were obtained at 8 and 18 months, respectively; she never crawled and walked only
15
16 with support until 5 and ½ y.o., when she began walking independently, although to this
17
18 date she prefers to sit or stand with support, when not prompted to walk; sphincter
19
20 control has not yet been acquired. Motor coordination is severely impaired. Babbling
21
22 began at 10 months and never evolved into expressive language. Non-verbal
23
24 communication, including pointing, is also absent. Stereotypic hand movements for
25
26 visual self-stimulation are frequent. Additional sensory self-stimulation involves
27
28 chewing on toys and occasionally fixating rotating objects. Upper limb mannerisms and
29
30 transient choreic movements are observed. The patient consistently turns when called by
31
32 name and her visual engagement has improved over time. Imitation skills have begun
33
34 emerging only after 4 ½ years of age. At kindergarden she appeared quiet, open to
35
36 interaction with peers but limited by motor and cognitive deficits. No aggressiveness
37
38 toward self or others was ever observed. Her sleep-wake cycle is disturbed by frequent
39
40 night awakenings, but her overall daily sleep time is sizable. Adherence to routines and
41
42 insistence-on-sameness are relevant, especially with regard to her daily schedule.
43
44 Allergic to milk and egg, she only eats soft foods and has been diagnosed with coeliac
45
46 disease following tests performed for chronic constipation. No seizure or absence ever
47
48 occurred, nor recurrent ear/upper airways infections.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Auxometric parameter include head circumference at 3rd-5th percentile, height at
5
6 25th percentile and weight at <<3rd percentile. Facial dysmorphisms include depressed
7
8 nasal bridge, telecanthus, frontal bossing with high anterior hairline, low-set ears,
9
10 slightly prominent glabella, infraorbital creases, prognatism, long filter, thin upper lip,
11
12 pointed chin (Figure 3a, b); cranial dysmorphisms include brachycephaly with flattened
13
14 occiput and positional plagiocephaly. No dysmorphisms are present in trunk and limbs.
15
16 Feet display mallet toes (Figure 3c). Otoacoustic emissions and auditory evoked-
17
18 potentials, EEG, brain MRI, fragile-X screening and karyotype were all normal.
19
20
21

22
23 Parents do not report present or past neuro- or psychopathology. Paternal family
24
25 history is positive for ID, brain tumor, alcoholism, bulimia and Arnold-Chiari
26
27 malformation; maternal family history is positive for schizophrenia, mild ID and
28
29 depression. Spontaneous abortions and infertility were also reported among maternal
30
31 and paternal family members, respectively.
32
33

34 Array-CGH unveiled a paternally inherited 467 kb deletion (chr2:50,713,464–
35
36 51,180,620/hg19) and a maternally inherited 269 kb deletion (chr2:50,982,113–
37
38 51,251,557), both disrupting exclusively the *NRXN1* locus and partly overlapping in bp
39
40 50,982,113-51,180,620, yielding nullisomy by compound heterozygosity (Figure 3d).
41
42
43
44

45 **3.2.2 Shared phenotypic features in *NRXN1* nullisomy and genotype-phenotype** 46 47 **correlations** 48

49
50 Comparison of the phenotypic features present in the eleven patients carrying
51
52 biallelic *NRXN1* deletions/mutations, as listed in Table 2, allows the identification of the
53
54 following “core” clinical correlates of *NRXN1* nullisomy: DD/ID, severe muscle
55
56 hypotonia, absence of expressive language, social interaction deficits, motor
57
58
59
60

1
2
3
4 stereotypies, abnormal sleep-wake cycle and chronic constipation. Additional features,
5 such as failure to thrive, strabismus, seizures, hyperventilation, hearing impairment,
6 microcephaly, electrophysiological and neuroanatomical abnormalities, are present in a
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

stereotypies, abnormal sleep-wake cycle and chronic constipation. Additional features, such as failure to thrive, strabismus, seizures, hyperventilation, hearing impairment, microcephaly, electrophysiological and neuroanatomical abnormalities, are present in a sizable minority of cases (Table 2).

With a single exception,⁸³ all *NRXNI* defects were inherited from healthy parents (Table 2); all are exonic, except for a boy carrying a homozygous intronic biallelic deletion, whose pathogenicity is uncertain due to parental consanguinity allowing alternative recessive explanations.⁸⁵ Two patients are compound heterozygous for a deletion and a point mutation, namely a nonsense mutation in exon 15 and a splice mutation, both leading to a truncated neurexin 1- α protein and to a clinical condition similar to the one observed in the presence of compound heterozygous deletions.^{57,83,87} The only subject carrying two point mutations has a clinical diagnosis of Pitt-Hopkins-like syndrome 2, although a missense mutation of uncertain significance and a silent substitution are unlikely to cause his severe condition,⁸⁶ which could well be caused by the missense mutation on one allele and an unidentified alteration on the second allele.

As described for heterozygous deletions, most exonic deletions in Pitt-Hopkins-like syndrome 2 span the promoter region and the first few exons of the *NRXNI- α* transcript, sparing the *NRXNI- β* transcript (Figure 2). The only exception is reported by Harrison et al,⁸² who proposed that *NRXNI- β* deletions may possibly be associated with early puberty in girls. The α - and β - isoforms interact differently with their binding partners, so the loss of both isoforms could lead to more severe loss of protein functions at the synapse. Functional redundancy between the various neurexin α - and β - isoforms is certainly not complete, given the abnormal phenotypes in mice and humans with homozygous loss of *NRXNI- α* .

1
2
3
4 Genotype-phenotype correlations are also complicated by the presence of
5 additional CNVs present in the genome of some patients. In particular, three patients
6 listed in Table 2 carry a deletion also spanning *miR-NID1* (*miR-8485*), located in the
7 fifth intron of *NRXN1* (Figure 2). This miRNA directly binds to TDP-43 and this
8 interaction results in repression of *NRXN1* gene expression.⁸⁸ There are no apparent
9 phenotypic differences between these three patients and those with biallelic *NRXN1*
10 deletions sparing *miR-8485*, so its phenotypic relevance is still unclear.
11
12
13
14
15
16
17
18
19
20
21
22

23 **4. RECOMMENDATIONS FOR CLINICAL PRACTICE**

24 The association of *NRXN1* deletions with several human disease phenotypes
25 underscores their clinical relevance. Indeed converging lines of evidence firmly
26 establish *NRXN1* deletions as risk factors for a variety of neurological, psychiatric and
27 neurodevelopmental disorders, like other recurrent CNVs endowed with incomplete
28 penetrance. Nonetheless, genetic counseling remains a challenge, especially when the
29 phenotype is atypical or includes congenital malformations. *It is not possible at this*
30 *time to reliably predict the clinical outcome of a heterozygous exonic NRXN1 deletion*
31 *detected through prenatal testing.* In these cases, it is advisable to set up a periodic
32 neuro-behavioral follow-up program for the timely detection of warning signs and the
33 prescription of early interventions possibly effective on neurodevelopmental
34 deficits.^{89,90} It is also important to consider that *NRXN1* deletion carriers reported in the
35 Literature likely represent the severe end of a phenotypic spectrum and, as discussed
36 above, *NRXN1* deletions likely require “second-hit” genetic contributors, able to
37 synergistically impair neurodevelopment and push phenotypic severity above clinical
38 threshold. Hence, *the presence of additional independent genetic risk factors should be*
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 *sought in NRXN1 deletion carriers.* Large population-based and clinical cohort studies,
5
6
7 as well as longitudinal follow-up studies able to catch late-onset phenotypes, such as
8
9 schizophrenia and depression, will indeed represent a key area of future research, aimed
10
11 at enhancing the reliability of genetic counselling and the efficacy of targeted
12
13 therapeutic interventions in the presence of mono-allelic *NRXN1* deletions.
14

15
16 Our phenotypic review of Pitt-Hopkins-like syndrome 2 bears another important
17
18 consequence in clinical practice: *the diagnostic work-up of heterozygous exonic NRXN1*
19
20 *deletion carriers must include DNA sequencing of the spared NRXN1 allele in search*
21
22 *for mutations or very small insertions/deletions, when children display early-onset,*
23
24 *severe psychomotor delay in the context of a Pitt-Hopkins-like syndrome 2 phenotype.*
25
26 Genetic and genomic defects affecting the *NRXN1* locus seemingly produce this
27
28 extreme degree of clinical severity and full penetrance only in the presence of
29
30 nullisomy, which may not be entirely explained by CGH-array alone.
31
32
33
34
35

36 **CONFLICT OF INTEREST**

37
38
39 The authors declare no conflict of interest.
40
41
42

43 **DATA AVAILABILITY STATEMENT**

44
45
46 Data sharing is not applicable to this article as no new data were created or analyzed in
47
48 this study.
49
50
51

52 **ORCID**

53
54
55 A.M. Persico. <http://orcid.org/0000-0001-8910-4479>
56

57
58
59 C. Lintas <http://orcid.org/0000-0003-1209-8554>
60

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the Pitt-Hopkins-like syndrome 2 patient described in this article and her family for their cooperation. This work was funded by the Italian Ministry of Health (Grant n. NET-2013-02355263) and the EU Innovative Medicines Initiative Joint Undertaking, EU-AIMS (Grant n. 115300).

5. REFERENCES

1. Reissner C, Runkel F, Missler M. Neurexins. *Genome Biol* 2013;14:213.
2. Tabuchi K, Südhof TC. Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing. *Genomics* 2002;79:849-859.
3. Li J, Ashley J, Budnik V, Bhat, MA. Crucial role of Drosophila neurexin in proper active zone apposition to postsynaptic densities, synaptic growth, and synaptic transmission. *Neuron* 2007; 55:741-755.
4. Missler M, Zhang W, Rohlmann A, et al. Alpha-neurexins couple Ca²⁺ channels to synaptic vesicle exocytosis. *Nature* 2003; 423:939-948.
5. Comoletti D, Flynn RE, Boucard AA, et al. Gene selection, alternative splicing, and post-translational processing regulate neuroligin selectivity for beta-neurexins. *Biochemistry* 2006; 45:12816-12827.
6. Petrenko AG, Ullrich B, Missler M. Structure and evolution of neurexophilin. *J Neurosci* 1996; 16:4360-4369.

- 1
2
3
4 7. Treutlein B, Gokce O, Quake SR, Südhof TC. Cartography of neurexin alternative
5 splicing mapped by single-molecule long-read mRNA sequencing. *Proc Natl Acad*
6
7 *Sci USA* 2014; 111:E1291-1299.
8
9
- 10
11 8. Rowen L, Young J, Birditt B, et al. Analysis of the human neurexin genes:
12 alternative splicing and the generation of protein diversity. *Genomics* 2002; 79:587-
13
14 597.
15
16
- 17
18 9. Enggaard Hoeffding LK, Hansen T, Ingason A, et al. Sequence analysis of 17
19 NRXN1 deletions. *Am J Med Genet B Neuropsychiatr Genet* 2014; 165B:52-61.
20
21
- 22
23 10. Chen X, Shen Y, Zhang F, et al. Molecular analysis of a deletion hotspot in the
24 NRXN1 region reveals the involvement of short inverted repeats in deletion CNVs.
25
26 *Am J Hum Genet* 2013; 92:375-386.
27
28
- 29
30 11. Zhou W, Zhang F, Chen X, et al. Increased genome instability in human DNA
31 segments with self-chains: homology-induced structural variations via replicative
32
33 mechanisms. *Hum Mol Genet* 2013; 22:2642-2651.
34
35
- 36
37 12. Lowther C, Speevak M, Armour CM, et al. Molecular characterization of NRXN1
38 deletions from 19,263 clinical microarray cases identifies exons important for
39
40 neurodevelopmental disease expression. *Genet Med* 2017; 19:53-61.
41
42
- 43
44 13. Dabell MP, Rosenfeld JA, Bader P, et al. Investigation of NRXN1 deletions:
45 clinical and molecular characterization. *Am J Med Genet A* 2013; 161A:717-731.
46
47
- 48
49 14. Walker S, Scherer SW. Identification of candidate intergenic risk loci in autism
50
51 spectrum disorder. *BMC Genomics* 2013; 14:499.
52
53
- 54
55 15. Duong LT, Hoeffding LK, Petersen KB, et al. Two rare deletions upstream of the
56 NRXN1 gene (2p16.3) affecting the non-coding mRNA AK127244 segregate with
57
58
59
60

- 1
2
3
4 diverse psychopathological phenotypes in a family. *Eur J Med Genet* 2015; 58:650-
5
6 653.
7
8
9 16. Pedrosa E, Kaushik S, Lachman HM. ChIP-chip analysis of neurexins and other
10
11 candidate genes for addiction and neuropsychiatric disorders. *J Neurogenet* 2010;
12
13 24:5-17.
14
15 17. Rizzo A, Alfei E, Zibordi F, et al. The noncoding RNA AK127244 in 2p16.3 locus:
16
17 A new susceptibility region for neuropsychiatric disorders. *Am J Med Genet B*
18
19 *Neuropsychiatr Genet* 2018; 177:557-562.
20
21
22 18. Rujescu D, Ingason A, Cichon S, et al. Disruption of the neurexin 1 gene is
23
24 associated with schizophrenia. *Hum Mol Genet* 2009; 18:988-996.
25
26
27 19. Møller RS, Weber YG, Klitten LL, et al. Exon-disrupting deletions of NRXN1 in
28
29 idiopathic generalized epilepsy. *Epilepsia* 2013; 54:256-264.
30
31
32 20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic
33
34 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;
35
36 4:1.
37
38
39 21. Béna F, Bruno DL, Eriksson M, et al. Molecular and clinical characterization of 25
40
41 individuals with exonic deletions of NRXN1 and comprehensive review of the
42
43 Literature. *Am J Med Genet B Neuropsychiatr Genet* 2013; 162B:388-403.
44
45
46 22. Napolioni V, Lombardi F, Sacco R, et al. Family-based association study of ITGB3
47
48 in autism spectrum disorder and its endophenotypes. *Eur J Hum Genet* 2011;
49
50 19:353-359.
51
52
53 23. Friedman JM, Baross A, Delaney AD, et al. Oligonucleotide microarray analysis of
54
55 genomic imbalance in children with mental retardation. *Am J Hum Genet* 2006;
56
57 79:500-513.
58
59
60

- 1
2
3
4 24. Guilmatre A, Dubourg C, Mosca AL, et al. Recurrent rearrangements in synaptic
5 and neurodevelopmental genes and shared biologic pathways in schizophrenia,
6
7 and autism, and mental retardation. *Arch Gen Psychiatry* 2009; 66:947-956.
8
9
- 10
11 25. Ching MS, Shen Y, Tan WH, et al. Deletions of NRXN1 (neurexin-1) predispose to
12 a wide spectrum of developmental disorders. *Am J Med Genet B Neuropsychiatr*
13
14
15
16
17 *Genet* 2010; 153B:937-947.
- 18 26. Sahoo T, Theisen A, Rosenfeld JA, et al. Copy number variants of schizophrenia
19 susceptibility loci are associated with a spectrum of speech and developmental
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27. Gregor A, Albrecht B, Bader I, et al. Expanding the clinical spectrum associated
with defects in CNTNAP2 and NRXN1. *BMC Med Genet* 2011; 12:106.
28. Schaaf CP, Boone PM, Sampath S, et al. Phenotypic spectrum and genotype-
phenotype correlations of NRXN1 exon deletions. *Eur J Hum Genet* 2012;
20:1240-1247.
29. Utine GE, Haliloğlu G, Volkan-Salancı B, et al. Etiological yield of SNP
microarrays in idiopathic intellectual disability. *Eur J Paediatr Neurol* 2014;
18:327-337.
30. Roberts JL, Hovanes K, Dasouki M, Manzardo AM, Butler MG. Chromosomal
microarray analysis of consecutive individuals with autism spectrum disorders or
learning disability presenting for genetic services. *Gene* 2014; 535:70-78.
31. Wolfe K, Strydom A, Morrogh D. Chromosomal microarray testing in adults with
intellectual disability presenting with comorbid psychiatric disorders. *Eur J Hum*
Genet 2016; 25:66-72.

- 1
- 2
- 3
- 4 32. Szatmari P, Paterson AD, Zwaigenbaum L, et al. Mapping autism risk loci using
- 5 genetic linkage and chromosomal rearrangements. *Nat Genet* 2007; 39:319-328.
- 6
- 7
- 8
- 9 33. Marshall CR, Noor A, Vincent JB, et al. Structural variation of chromosomes in
- 10 autism spectrum disorder. *Am J Hum Genet* 2008; 82:477-488.
- 11
- 12
- 13 34. Bucan M, Abrahams BS, Wang K, et al. Genome-wide analyses of exonic copy
- 14 number variants in a family-based study point to novel autism susceptibility genes.
- 15 *PLoS Genet* 2009; 5:e1000536.
- 16
- 17
- 18
- 19
- 20 35. Glessner JT, Wang K, Cai G, et al. Autism genome-wide copy number variation
- 21 reveals ubiquitin and neuronal genes. *Nature* 2009; 459:569-573.
- 22
- 23
- 24
- 25 36. Sanders SJ, Ercan-Sencicek AG, Hus V, et al. Multiple recurrent de novo CNVs,
- 26 including duplications of the 7q11.23 Williams syndrome region, are strongly
- 27 associated with autism. *Neuron* 2011; 70:863-885.
- 28
- 29
- 30
- 31
- 32 37. Prasad A, Merico D, Thiruvahindrapuram B, et al. A discovery resource of rare
- 33 copy number variations in individuals with autism spectrum disorder. *G3*
- 34 *(Bethesda)* 2012; 2:1665-1685.
- 35
- 36
- 37
- 38
- 39 38. Gai X, Xie HM, Perin JC, et al. Rare structural variation of synapse and
- 40 neurotransmission genes in autism. *Mol Psychiatry* 2012; 17:402-411.
- 41
- 42
- 43
- 44 39. Hedges DJ, Hamilton-Nelson KL, Sacharow SJ, et al. Evidence of novel fine-scale
- 45 structural variation at autism spectrum disorder candidate loci. *Mol Autism* 2012;
- 46 3:2.
- 47
- 48
- 49
- 50 40. Girirajan S, Dennis MY, Baker C, et al. Refinement and discovery of new hotspots
- 51 of copy-number variation associated with autism spectrum disorder. *Am J Hum*
- 52 *Genet* 2013; 92:221-237.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4 41. Görker I, Gürkan H, Ulusal S, et al. Investigation of Copy Number Variation by
5 arrayCGH in Turkish children and adolescents diagnosed with Autism Spectrum
6 Disorders. *Noro Psikiyatr Ars* 2018; 55:215-219.
7
8
- 9
10
11 42. Kirov G, Gumus D, Chen W, et al. Comparative genome hybridization suggests a
12 role for NRXN1 and APBA2 in schizophrenia. *Hum Mol Genet* 2008; 17:458-465.
13
- 14
15 43. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt
16 multiple genes in neurodevelopmental pathways in schizophrenia. *Science* 2008;
17 320:539-543.
18
19
- 20
21
22 44. Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, et al. Recurrent CNVs disrupt
23 three candidate genes in schizophrenia patients. *Am J Hum Genet* 2008; 83:504-
24 510.
25
26
- 27
28
29 45. International Schizophrenia Consortium. Rare chromosomal deletions and
30 duplications increase risk of schizophrenia. *Nature* 2008; 455:237-241.
31
32
- 33
34 46. Need AC, Ge D, Weale ME, et al. A genome-wide investigation of SNPs and
35 CNVs in schizophrenia. *PLoS Genet* 2009; 5:e1000373.
36
37
- 38
39 47. Kirov G, Grozeva D, Norton N, et al. Support for the involvement of large copy
40 number variants in the pathogenesis of schizophrenia. *Hum Mol Genet* 2009;
41 18:1497-1503.
42
43
- 44
45 48. Bradley WE, Raelson JV, Dubois DY, et al. Hotspots of large rare deletions in the
46 human genome. *PLoS One* 2010; 5:e9401.
47
48
- 49
50 49. Magri C, Sacchetti E, Traversa M, et al. New copy number variations in
51 schizophrenia. *PLoS One* 2010; 5:e13422.
52
53
- 54
55 50. Ikeda M, Aleksic B, Kirov G, et al. Copy number variation in schizophrenia in the
56 Japanese population. *Biol Psychiatry* 2010; 67:283-286.
57
58
59
60

- 1
2
3
4 51. Levinson DF, Duan J, Oh S, et al. Copy number variants in schizophrenia:
5
6 confirmation of five previous findings and new evidence for 3q29 microdeletions
7
8 and VIPR2 duplications. *Am J Psychiatry* 2011; 168:302-316.
- 9
10
11 52. Levinson DF, Shi J, Wang K, et al. Genome-wide association study of multiplex
12
13 schizophrenia pedigrees. *Am J Psychiatry* 2012; 169:963-973.
- 14
15
16 53. Van Den Bossche MJ, Strazisar M, Cammaerts S, et al. Identification of rare copy
17
18 number variants in high burden schizophrenia families. *Am J Med Genet B*
19
20 *Neuropsychiatr Genet* 2013; 162B:273-282.
- 21
22
23 54. Rees E, Walters JT, Georgieva L, et al. Analysis of copy number variations at 15
24
25 schizophrenia-associated loci. *Br J Psychiatry* 2014; 204:108-114.
- 26
27
28 55. Todarello G, Feng N, Kolachana BS, et al. Incomplete penetrance of NRXN1
29
30 deletions in families with schizophrenia. *Schizophr Res* 2014; 155:1-7.
- 31
32
33 56. Li Z, Chen J, Xu Y, et al. Genome-wide analysis of the role of copy number
34
35 variation in schizophrenia risk in Chinese. *Biol Psychiatry* 2016; 80:331-337.
- 36
37
38 57. Zweier C, de Jong EK, Zweier M, et al. CNTNAP2 and NRXN1 are mutated in
39
40 autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of
41
42 a common synaptic protein in Drosophila. *Am J Hum Genet* 2009; 85:655-666.
- 43
44
45 58. Sundaram SK, Huq AM, Wilson BJ, Chugani HT. Tourette syndrome is associated
46
47 with recurrent exonic copy number variants. *Neurology* 2010; 74:1583-1590.
- 48
49
50 59. Stewart LR, Hall AL, Kang SH, Shaw CA, Beaudet AL. High frequency of known
51
52 copy number abnormalities and maternal duplication 15q11-q13 in patients with
53
54 combined schizophrenia and epilepsy. *BMC Med Genet* 2011; 12:154.
- 55
56
57 60. Curran S, Ahn JW, Grayton H, Collier DA, Ogilvie CM. NRXN1 deletions
58
59 identified by array comparative genome hybridisation in a clinical case series -
60

1
2
3
4 further understanding of the relevance of NRXN1 to neurodevelopmental disorders.

5
6
7 *J Mol Psychiatry* 2013; 1:4.

- 8
9 61. Møller RS, Weber YG, Klitten LL, et al. Exon-disrupting deletions of NRXN1 in
10 idiopathic generalized epilepsy. *Epilepsia* 2013; 54:256-264.
- 11
12
13 62. Nicholl J, Waters W, Suwalski S, et al. Epilepsy with cognitive deficit and autism
14 spectrum disorders: prospective diagnosis by array CGH. *Am J Med Genet B*
15 *Neuropsychiatr Genet* 2013; 162B:24-35.
- 16
17
18 63. Noor A, Lionel AC, Cohen-Woods S, et al. Copy number variant study of bipolar
19 disorder in Canadian and UK populations implicates synaptic genes. *Am J Med*
20 *Genet B Neuropsychiatr Genet* 2014; 165B:303-313.
- 21
22
23 64. Nag A, Bochukova EG, Kremeyer B, et al. CNV analysis in Tourette syndrome
24 implicates large genomic rearrangements in COL8A1 and NRXN1. *PLoS One*
25 2013; 8:e59061.
- 26
27
28 65. Wang JC, Mahon LW, Ross LP1, et al. Enrichment of small pathogenic deletions at
29 chromosome 9p24.3 and 9q34.3 involving DOCK8, KANK1, EHMT1 genes
30 identified by using high-resolution oligonucleotide-single nucleotide polymorphism
31 array analysis. *Mol Cytogenet* 2016; 9:82.
- 32
33
34 66. Pérez-Palma E, Helbig I, Klein KM, et al. Heterogeneous contribution of
35 microdeletions in the development of common generalised and focal epilepsies. *J*
36 *Med Genet* 2017; 54:598-606.
- 37
38
39 67. Grünblatt E, Oneda B, Ekici AB, et al. High resolution chromosomal microarray
40 analysis in paediatric obsessive-compulsive disorder. *BMC Med Genomics* 2017;
41 10:68.
- 42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 68. Huang AY, Yu D, Davis LK, et al. Rare Copy Number Variants in NRXN1 and
5
6 CNTN6 Increase Risk for Tourette Syndrome. *Neuron* 2017; 94:1101-1111.
7
8
9 69. Gonzalez-Mantilla AJ, Moreno-De-Luca A, Ledbetter DH, Martin CL. A Cross-
10
11 Disorder Method to Identify Novel Candidate Genes for Developmental Brain
12
13 Disorders. *JAMA Psychiatry* 2016;73:275-283.
14
15
16 70. Al Shehhi M, Forman EB, Fitzgerald JE, et al. NRXN1 deletion syndrome;
17
18 phenotypic and penetrance data from 34 families. *Eur J Med Genet* 2018 Jul 18.
19
20 doi: 10.1016/j.ejmg.2018.07.015. [Epub ahead of print]
21
22
23 71. Brignell A, St John M, Boys A, et al. Characterization of speech and language
24
25 phenotype in children with NRXN1 deletions. *Am J Med Genet B Neuropsychiatr*
26
27 *Genet* 2018 Oct 25. doi: 10.1002/ajmg.b.32664.
28
29
30 72. Saito A, Miyauchi N, Hashimoto T, et al. Neurexin-1, a presynaptic adhesion
31
32 molecule, localizes at the slit diaphragm of the glomerular podocytes in kidneys.
33
34 *Am J Physiol Regul Integr Comp Physiol* 2011; 300:R340-348.
35
36
37 73. Zahir FR, Baross A, Delaney AD, et al. A patient with vertebral, cognitive and
38
39 behavioural abnormalities and a *de novo* deletion of NRXN1alpha. *J Med Genet*
40
41 2008; 45:239-243.
42
43
44 74. Wiśniowiecka-Kowalnik B, Nesteruk M, Peters SU, et al. Intragenic
45
46 rearrangements in NRXN1 in three families with autism spectrum disorder,
47
48 developmental delay, and speech delay. *Am J Med Genet B Neuropsychiatr Genet*
49
50 2010; 153B:983-993.
51
52
53 75. Etherton MR, Blaiss CA, Powell CM, Südhof TC. Mouse neurexin-1alpha deletion
54
55 causes correlated electrophysiological and behavioral changes consistent with
56
57 cognitive impairments. *Proc Natl Acad Sci U S A* 2009;106:17998-18003.
58
59
60

- 1
2
3
4 76. Dachtler J, Ivorra JL, Rowland TE, Lever C, Rodgers RJ, Clapcote SJ.
5
6 Heterozygous deletion of α -neurexin I or α -neurexin II results in behaviors relevant
7
8 to autism and schizophrenia. *Behav Neurosci* 2015; 129:765-776.
9
10
11 77. Persico AM, Merelli S. Environmental factors and Autism Spectrum Disorder. *Curr*
12
13 *Dev Disord Rep* 2014; 1:8-19.
14
15
16 78. Bölte S, Girdler S, Marschik PB. The contribution of environmental exposure to the
17
18 etiology of autism spectrum disorder. *Cell Mol Life Sci* 2018 Dec 20.
19
20 doi:10.1007/s00018-018-2988-4. [Epub ahead of print]
21
22
23 79. Viñas-Jornet M, Esteba-Castillo S, Gabau E, et al. A common cognitive,
24
25 psychiatric, and dysmorphic phenotype in carriers of NRXN1 deletion. *Mol Genet*
26
27 *Genomic Med* 2014; 2:512-521.
28
29
30 80. Stefansson H, Meyer-Lindenberg A, Steinberg S, et al. CNVs conferring risk of
31
32 autism or schizophrenia affect cognition in controls. *Nature* 2014; 505:361-366.
33
34
35 81. Grayton HM, Missler M, Collier DA, Fernandes C. Altered social behaviours in
36
37 neurexin 1 α knockout mice resemble core symptoms in neurodevelopmental
38
39 disorders. *PLoS One* 2013;8:e67114.
40
41
42 82. Harrison V, Connell L, Hayesmoore J, et al. Compound heterozygous deletion of
43
44 NRXN1 causing severe developmental delay with early onset epilepsy in two
45
46 sisters. *Am J Med Genet A* 2011; 155A:2826-2831.
47
48
49 83. Duong L, Klitten LL, Møller RS, et al. Mutations in NRXN1 in a family multiply
50
51 affected with brain disorders: NRXN1 mutations and brain disorders. *Am J Med*
52
53 *Genet B Neuropsychiatr Genet* 2012; 159B:354-358.
54
55
56
57
58
59
60

- 1
2
3
4 84. Imitola J, Walleigh D, Anderson CE, et al. Fraternal twins with autism, severe
5 cognitive deficit, and epilepsy: diagnostic role of chromosomal microarray analysis.
6
7
8
9 *Semin Pediatr Neurol* 2014; 21:167-171.
- 10
11 85. Holmquist P. A boy with dysmorphic features, intellectual disability, and biallelic
12 homozygous deletion in NRXN1. *Clin Dysmorphol* 2015; 24:75-78.
- 13
14
15 86. Ruiz-Botero F, Gómez-Pineda E, Pachajoa H. A new case of Pitt-Hopkins-like
16 syndrome 2? *Neurologia* 2017; e-pub ahead of print 23 Mar 2017; doi:
17
18 10.1016/j.nrl.2017.01.018.
- 19
20
21
22 87. Gauthier J, Siddiqui TJ, Huashan P, et al. Truncating mutations in NRXN2 and
23 NRXN1 in autism spectrum disorders and schizophrenia. *Hum Genet* 2011; 4:563-
24
25 573.
- 26
27
28 88. Fan Z, Chen X, Chen R. Transcriptome-wide analysis of TDP-43 binding small
29 RNAs identifies miR-NID1 (miR-8485), a novel miRNA that represses NRXN1
30 expression. *Genomics* 2014; 103:76-82.
- 31
32
33
34 89. Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention
35 (EIBI) for young children with autism spectrum disorders (ASD). *Cochrane*
36
37 *Database Syst Rev* 2012; 10:CD009260.
- 38
39
40
41 90. Estes A, Munson J, Rogers SJ, Greenson J, Winter J, Dawson G. Long-term
42 outcomes of early intervention in 6-year-old children with Autism Spectrum
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE AND TABLE LEGENDS

Figure 1. Flowchart of the Literature search.

Figure 2. Location of compound heterozygous deletions described so far, in reference to *NRXNI* α and β isoforms (top). Horizontal bars represent deletions, vertical bars represent point mutations.

Figure 3. Phenotypic and molecular findings in our new case of *NRXNI* nullisomy. **(a)**, **(b)** Facial and cranial dysmorphisms; **(c)** Mallet toes; **(d)** Array-CGH profile of the proband shown in parallel with the 467 kb paternal deletion at 2p16.3 (chr2:50,713,464–51,180,620) and the 269 kb maternal deletion (chr2:50,982,113–51,251,557).

Table 1. List of case/control studies describing the frequency and characteristics of monoallelic *NRXNI* exonic deletions ordered by disease phenotype.

Table 2. Phenotypic and molecular characteristics of individuals with biallelic *NRXNI* deletions/mutations. “Core” phenotypic features shared by most or all patients are highlighted in gray.




Figure 1. Flowchart of the Literature search.

180x232mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Location of compound heterozygous deletions described so far, in reference to NRXN1 α and β isoforms (top). Horizontal bars represent deletions, vertical bars represent point mutations.

55x31mm (300 x 300 DPI)




Figure 3. Phenotypic and molecular findings in our new case of NRXN1 nullisomy. (a, b) Facial and cranial dysmorphisms; (c) Mallet toes; (d) Array-CGH profile of the proband shown in parallel with the 467 kb paternal deletion at 2p16.3 (chr2:50,713,464–51,180,620) and the 269 kb maternal deletion (chr2:50,982,113–51,251,557).

33x30mm (300 x 300 DPI)

Reference	only α exons	α and β exons	Unspecified location	Cases tested	Frequency of exonic deletions in cases (%)	Deletions in controls	Controls tested	Frequency of exonic deletions in controls (%)
DD/ID cohorts								
Friedman et al (2006) ²²	1	0	0	100	1.00	NA	NA	NA
Guilmatre et al (2009) ²³	1	0	0	247	0.40	0	236	0
Ching et al (2010) ²⁴	7	2	0	3540	0.25	10	51939	0.02
Sahoo et al (2011) ²⁵	12	3	0	1150	1.30	NA	NA	NA
Gregor et al (2011) ²⁶	1	0	0	45	2.22	NA	NA	NA
Schaaf et al (2012) ²⁷	8	3	0	8051	0.14	NA	NA	NA
Chen et al (2013) ¹⁰	12	0	0	6623	0.18	NA	NA	NA
Dabell et al (2013) ¹³	27	2	0	25610	0.11	NA	NA	NA
Utine et al (2014) ²⁸	1	0	0	100	1.00	NA	NA	NA
Roberts et al (2014) ²⁹	0	0	0	150	0.00	NA	NA	NA
Wolfe et al (2017) ³⁰	1	0	0	202	0.50	NA	NA	NA
Sum of DD/ID cohorts	71	10	0	45818	0.18	10	52175	0.02
ASD cohorts								
Szatmari et al (2007) ³¹	0	1	0	173	0.58	NA	NA	NA
Marshall et al (2008) ³²	1	0	0	427	0.23	0	1652	0
Bucan et al (2009) ³³	4	0	5	1771	0.51	0	2539	0
Guilmatre et al (2009) ²³	2	0	0	260	0.77	0	236	0
Glessner et al (2009) ³⁴	3	0	3	1637	0.37	0	2519	0
Sanders et al (2011) ³⁵	3	0	0	1124	0.27	NA	NA	NA
Prasad et al (2012) ³⁶	0	0	2	676	0.30	NA	1000	NA
Gai et al (2012) ³⁷	2	0	0	689	0.29	NA	NA	NA
Hedges et al (2012) ³⁸	1	0	0	168	0.60	1	149	0.67
Chen et al (2013) ¹⁰	2	0	0	751	0.27	1	13991	0.01
Girirajan et al (2013) ³⁹	7	0	0	2588	0.27	1	2770	0.04
Roberts et al (2014) ²⁹	0	0	0	65	0.00	NA	NA	NA
Görker et al (2018) ⁴⁰	1	0	0	53	1.89	NA	NA	NA
Sum of ASD cohorts	26	1	10	10382	0.36	3	23856	0.01

Pérez-Palma et al (2017) (GGE/RE/AFE) ⁶⁵	0	0	3	2454	0.12	0	6476	0
Grünblatt et al (2017) (OCD) ⁶⁶	1	0	0	121	0.83	0	124	0
Huang 2017 (TS) ⁶⁷	0	0	12	2434	0.49	1	4093	0.02
Rizzo et al (2018) (NCD) ¹⁷	9	2	0	2470	0.45	NA	NA	NA
Sum of mixed cohorts	33	6	97	79115	0.17	7	34263	0.02
Sum of all cohorts	173	20	112	166285	0.18	29	162434	0.02

Abbreviations: DD/ID: Developmental Delay/Intellectual Disability; ASD: Autism Spectrum Disorder; SCZ: schizophrenia; PTHS: Pitt-Hopkins Syndrome; ADHD: Attention Deficit Hyperactivity Disorder; TS: Tourette Syndrome; E: Epilepsy; IGE: Idiopathic Generalised Epilepsy; MCA: Multiple Congenital Anomalies; BD: Bipolar Disorder; GGE: Genetic Generalized Epilepsy; RE:Rolandic Epilepsy; AFE: Adult Focal Epilepsy; OCD: Obsessive compulsive Disorder; NCD: Neurocognitive Disorders

For Review Only

Patients	Present case	Ruiz-Botero ⁸⁵	Holmquist et al ⁸⁴	Imitola et al ⁸³ Case 1
<i>NRXN1</i> deletions/mutations	(p) 467-kb del [chr2:50,713,464-51,180,620]	(p) c.1405C>T p.Pro469Ser [chr2:50,847,195]	(p) 170-kb del [chr2:50,871,825-51,036,925]	(ns) 107-kb del [chr2:51,047,060-51,154,995]
(p) paternal allele				
(m) maternal allele	(m) 269-kb del [chr2:50,982,113-51,251,557]	(m) c.4053A>G p.Ala1351Ala [chr2:50,280,606]	(m) 170-kb del [chr2:50,871,825-51,036,925]	(ns) 135-kb del [chr2:51,184,729-51,319,450]
(ns) not specified				
<i>NRXN1</i> isoform	α	$\alpha+\beta$	α	α
Other molecular findings	489-kb dup [chr15:32,021,733-32,510,863]	NR	NR	NR
Parental consanguinity	No	No	Yes	No
Family history	Depression, schizophrenia, brain tumor, Arnold-Chiari malformation, alcoholism, cognitive disability and bulimia	None	None	None
Age (years)	6	7	4	7
Sex	Female	Male	Male	Male
Height (centile)	25th	90,3th	<3rd	5th
Weight (centile)	<<3rd	34,5th	<3rd	10th
Head circumference	3-5th	60,8th	<<3rd (-4 sd)	25-50th
Developmental delay	Severe	Severe	Severe	Severe
Seizures	No	No	No	Yes, starting at 5 y.o.
EEG	Normal	NR	NR	Generalized paroxysmal spike wave followed by 2Hz delta waves
Age at walking	5.5 y.o.	2 y.o.	Unable to walk	2 y.o.

MRI-scan	Normal	Asymmetry of the posterior ventricular system with dilatation of a right ventricle, changes anatomical on the ventricular floor, great megacisterna and cerebellar lobes	Thin cerebral WM, periventricular high T2 signals and expanded Virchow-Robin spaces	Normal
Breathing abnormality	Hyperventilation	Hyperventilation	No	No
Hypotonia	Yes	Yes	Yes	Yes
Speech	No	No	No	2-10 words
Social interaction deficit	Severe	Severe	Severe	Severe
Intellectual disability	Severe	Severe	Severe	Severe
Motor stereotypies	Yes	Yes	Yes	Yes
Strabismus	No	Yes	Yes	NR
Hearing impairment	No	NR	Yes	NR
Failure to thrive	Yes	NR	Yes	NR
Dysmorphic features	Yes	Yes	Yes	NR
Chronic constipation	Yes	NR	NR	Yes
Abnormal sleep-wake cycle	Yes	No	NR	Yes
Other	Celiac disease. Milk and egg allergy.	Hyperactivity, self-injurious behavior, G-E reflux, severe autism, excessive drooling and hyporeflexia. Left ventricular hypertrophy; pulmonary stenosis and tricuspid insufficiency.	Bilateral undescended testes and inguinal hernias, increased liver aminotransferases, high-pitched cry, at birth elevated TSH and low ionized calcium.	Dysphagia, aggressive and self-harm behavior, ventricular septal defect.

Abbreviations: NR, not reported; G-E, gastroesophageal reflux; y.o., years old; EEG, electroencephalography; MRI, magnetic resonance imaging; TSH, thyroid-stimulating hormone

	Imitola et al⁸³	Utine et al²⁸	Béna et al²¹	Duong et al⁸²	Harrison et al⁸¹
	Case 2				Case 1
	(ns) 107-kb del [chr2:51,047,060-51,154,995]	(p) 130-kb del [NRXN1 ex 1-2]	(p) 400-kb del [chr2:51,109,690-51,510,961]	(p) c.IVS14-1G>A [chr2:50,723,234]	(p) 287-kb del [chr2:51,008,023-51,294,599]
	(ns) 135-kb del [chr2:51,184,720-51,320,000]	(m) 130-kb del [NRXN1 ex 1-2]	(m) 180-kb del [chr2:51,100,600-51,281,000]	(m) 451kb-del [chr2:50,812,891-51,263,512]	(m) 79-kb del [chr2:50,214,717-50,293,739]
	α	α	α	α	$\alpha+\beta$
	NR	NR	NR	NR	742-kb dup [chr5:168,866,009-169,607,847]
	No	Yes	NR	No	No
	None	NR	None	Paranoid schizophrenia, schizotypal personality disorder and bipolar disorder	None
	7	10	10	33	16
	Female	Male	Female	Male	Female
	5th	≤ 3 rd	NR	NR	<0.4th
	10th	≤ 3 rd	NR	NR	<0.4th
	<5th	≤ 3 rd	70th (+1 sd)	NR	0.4-9th
	Severe	Severe	Moderate	Severe	Severe
	No	Yes (intractable seizures)	Yes	Yes (West syndrome)	Yes (severe epileptic encephalopathy, starting at 6 months)
	Normal	NR	NR	Hypsarhythmia	Diffusely slow for age in wake; disorganized in sleep, with posterior epileptiform discharges limited to early childhood.
	2 y.o.	> 6 y.o.	NR	3 y.o.	5 y.o.

1					
2	NR	Normal	NR	Moderate cortical atrophy, cyst deflecting the right hippocampus	Normal
3					
4					
5					
6					
7					
8					
9	Hyperventilation	No	NR	No	Hyperventilation
10	Yes	NR	Yes	Yes	Yes
11	2-5 words	2 words	No	No	20-25 words
12	Severe	Severe	Severe	Severe	Severe
13	Severe	Severe	Severe	Severe	Severe
14	Severe	Severe	Severe	Severe	Severe
15	Yes	No	NR	Yes	Yes
16	Yes	NR	NR	Yes	No
17	NR	NR	NR	Yes	No
18	NR	Yes	No	No	Yes
19	NR	No	No	Yes	No
20	Yes	NR	NR	NR	Yes
21	Yes	No	NR	NR	Yes
22	Aggressive behavior.	NR.	Hyperactivity.	NR.	G-E- reflux requiring gastrostomy and fundoplication; scoliosis, pulmonary stenosis, early-onset puberty (age 9). Bruxism. Self-harm behavior.
23					
24					
25					
26					
27					
28					
29					
30					
31	hormone; WM, white matter				
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					

Harrison et al⁸¹ Case 2	Zweier et al⁵⁶
(p) 287-kb del [chr2:51,008,023-51,294,599]	(p) c.2936C>G, p.Ser979X [chr2:50,723,289]
(m) 79-kb del [chr2:50,214,717-50,293,739]	(m) 113-kb del [chr2:51,147,499- 51,260,172]
$\alpha+\beta$	α
742-kb dup [chr5:168,866,009-169,607,847]	NR
No	NR
None	None
11	18
Female	Female
25th	50-75th
25th	50-75th
9th	25th
Severe	Severe
Yes (severe myoclonic epilepsy with occasional atypical absences, starting at 4 months)	No
NR	NR
Unable to walk	2 y.o.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Normal	Normal
Breath holding	Hyperventilation
Yes	NR
No	No
Severe	Severe
Severe	Severe
Yes	Yes
No	Yes
No	No
Yes	No
No	Yes
Yes	Yes
Yes	Yes
G-E reflux, scoliosis, pulmonary stenosis, early- onset puberty (age 6).	Hyperactivity and excessive drooling.

For Review Only